May 20th 2021
Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.
February 15th 2020
Ledipasvir-Sofosbuvir Can Improve HCV-Mediated Neurocognitive Dysfunction
November 10th 2014A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C virus-infected patients, especially among those with mild disease.
Read More
HCV Care: Access and Cost of Treatment
November 10th 2014The efficacy of oral antivirals for hepatitis C infection is a moot point. The prevailing discussion now delves into the best combinations that can target different viral genotypes, access to these combination regimens, and the subsequent dent in the budget of the patient, the health plan, or the care provider-as the case may be.
Read More
The Global Economics of New HCV Treatments
November 10th 2014Medicare costs, Department of Veterans Affairs budgetary costs, and the economic impact on the developing world-these were some of the topics discussed at the evening session, Health Economics and Cost-Effectiveness, on the third day at The Liver Meeting 2014, held in Boston, Massachusetts, November 7 to 11, 2014.
Read More
Establishing Value in Hepatology Care
November 9th 2014Amidst discussions on liver care, transplants, and infections was a session on Value-Based Medicine in Hepatology, on the third day at The Liver Meeting 2014, an annual event by the American Association for the Study of Liver Disease, held in Boston, Massachusetts, from November 7 to 11, 2014. Presenters saw a huge turnout for the session, a sign of increased interest in value-based care.
Read More
Poster Round-Up: Clinical and Managed Care Outcomes
November 9th 2014A pattern is emerging in the hepatitis C virus treatment realm-of the newly approved agents, the sofosbuvir- and simeprevir-based regimens are gaining traction. A poster session on approved therapeutic agents on November 9, 2014, at the annual meeting of the American Association for the Study of Liver Disease, proved this again.
Read More
The Real-World Experience With Simeprevir- and Sofosbuvir-Based Regimens in Hep C Treatment
November 9th 2014Bashar A. Aqel, MD, Mayo Clinic, Phoenix, Arizona, presented results from phase 2 of the COSMOS (Combination Of SiMeprevir and sOfosbuvir in hepatitis C virus genotype 1 infected patients) trial.
Read More
The Cost Debate on HCV Treatment in Europe
November 8th 2014While the cost of hepatitis C treatment continues to be a major topic of debate-with the approval of simeprevir (Olysio), sofosbuvir (Sovaldi), and now the combination, sofosbuvir and ledipasvir (Harvoni)-those in favor of the treatment provide a strong research-based argument. The cost-debate is global, as shown by this cost-effectiveness study conducted in Italy.
Read More
Real-World Data on Novel Hep C Treatments
November 8th 2014While the cost of novel hepatitis C drugs has been rigorously debated, real-world data on the safety and efficacy of these drugs has now started showing up. A white paper released by CVS Health Research Institute in September of this year reported that in addition to the downward trend in utilization of sofosbuvir, which has cure rates of more than 95%, high discontinuation rates are being observed.
Read More
Gilead's Harvoni Less Expensive, but Still a Burden on State Medicaid Programs
October 13th 2014Gilead Sciences' Harvoni represents the first once-a-day, complete treatment pill approved by the FDA to treat the hepatitis C virus (HCV). And for some patients, the drug will be less expensive than Gilead's other HCV treatment, Sovaldi.
Read More
AJMC Sets Infectious Disease Meeting for Atlanta
June 19th 2014The American Journal of Managed Care will host a two-day event September 25-26, 2014, to take on some of healthcare's biggest challenges: Treatments that cure hepatitis C are making news but upending balance sheets. A recent recommendation seeks preventive therapy to stop new cases of HIV. Hospitals and public health officials are grappling with how to prevent the spread of MERS. Only AJMC will bring payers, clinicians, policy leaders, and pharmaceutical representatives together to share ideas.
Read More
VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients
April 17th 2014Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday.
Read More
Certain Patients May Wait for Newer Hepatitis C Drugs
March 12th 2014While newer drugs used to treat hepatitis C virus may be more effective, they may not always be the best value option for patients. This is because the costs of emerging treatments can range from $60,000 to $80,000 per treatment course, and that cost undermines the ultimate goals of lowering healthcare costs in the US.
Read More